arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Innoviva, Inc.

INVA
$19.21 ▼ -2.04 (-9.60%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
18 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
83
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Innoviva, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $1.3B
Dividend Yield —
Revenue Growth 14.7% ↘
Op. Margin 39.8% ↘
ROIC 9.5% ↘
FCF / Share $2.91 ↘
Trailing P/E 4.8x
Price / Book 1.2x
FCF Yield 15.1%
Debt / Equity 0.22
info Valuation on last close. End-of-day price, Nov 5, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$411.33M
↑ +14.7% —
Net Income Profit after all expenses
$271.17M
↑ +1059.2% —
Operating Margin Operating profit as % of sales
39.8%
↓ -14.4% 93th
FCF / Share Free cash flow per share
$2.91
↓ -3.3% —
Long-Term Debt Long-term obligations
$257.73M
↑ +0.6% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↓
97
Returns ↓
89
Financial Health ↓
76
Cash Quality ↓
50

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 68 quarters